10-Q quarterly report · filed Oct 29, 2026

SUPERNUS PHARMACEUTICALS, INC. (SUPN) Q3 2026 10-Q Quarterly Report

Short answer

SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $227M (up 18.0% year over year) with net income of $21M.

Q3 2026 key financials · XBRL

Revenue
$227M
+18.0% YoY · +3.5% QoQ
Net income
$21M
+146.4% YoY · +135.8% QoQ
Operating margin
9.3%
EPS (diluted)
$0.36
+145.0% YoY · +135.6% QoQ

Source: XBRL data from the SUPERNUS PHARMACEUTICALS, INC. (SUPN) Q3 2026 10-Q on SEC EDGAR. USD.

SUPERNUS PHARMACEUTICALS, INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $226.8M, up 18% YoY from $192.1M
  • Operating margin not disclosed; net loss $39.8M for nine months vs $34.4M YoY
  • Best performer: ONAPGO sales $17.1M, up 151% YoY; worst: APOKYN sales $6.5M, down 38%
  • Cash and securities $359.5M at September 30; operating cash flow $68.3M for nine months vs $27.5M YoY
  • Outlook: cash sufficient beyond twelve months; headwinds from generic erosion, payor pressure, and potential merger-related cash reduction

Risk Factors

  • Pending Indivior merger: completion conditions may fail or face delays, potentially causing material business disruption
  • Merger litigation: two New York complaints filed September 16-17, 2026, seeking injunctions and damages
  • Financing risk: Indivior’s $650 million Term Loan Facility may be unavailable, forcing an Alternative Dividend
  • Combined-company leverage: existing $500 million 0.625% Convertible Senior Notes due 2031 plus merger-related debt
  • Fixed exchange ratio: Supernus shareholders receive 1.5401 Indivior shares regardless of stock-price changes

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other SUPERNUS PHARMACEUTICALS, INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.